Hangzhou Just Bio Raises $57 Million for Biologic Drug Development

00:44 EDT 9 Aug 2017 | ChinaBio Today

Hangzhou Just Biotherapeutics (Just China), a company focused on providing affordable biologic drugs, completed a $57 million Series B funding. Just China is developing a portfolio of innovative and biosimilar products. Founded in early 2016 as a joint venture with Just Biotherapeutics (Just) of Seattle, Just China was established with the goal of shortening the development process and reducing the manufacturing cost of biologic drugs. The B round was led by Temasek of Singapore and joined by existing investors Lilly Asia Ventures and ARCH Venture Partners. More details....

Share this with colleagues:

Original Article: Hangzhou Just Bio Raises $57 Million for Biologic Drug Development


More From BioPortfolio on "Hangzhou Just Bio Raises $57 Million for Biologic Drug Development"

Quick Search

Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...